Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179012
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gil Gil, Miguel | - |
dc.contributor.author | Alba, Emilio | - |
dc.contributor.author | Gavilá, Joaquín | - |
dc.contributor.author | Haba Rodríguez, Juan de la | - |
dc.contributor.author | Ciruelos, Eva | - |
dc.contributor.author | Tolosa, Pablo | - |
dc.contributor.author | Candini, Daniele | - |
dc.contributor.author | Llombart Cussac, Antonio | - |
dc.date.accessioned | 2021-07-12T09:51:12Z | - |
dc.date.available | 2021-07-12T09:51:12Z | - |
dc.date.issued | 2021-07-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/179012 | - |
dc.description.abstract | The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.breast.2021.05.008 | - |
dc.relation.ispartof | The Breast, 2021, vol.58, p. 160-169 | - |
dc.relation.uri | https://doi.org/10.1016/j.breast.2021.05.008 | - |
dc.rights | CC BY (c) Gil Gil, Miguel et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Tractament adjuvant del càncer | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Adjuvant treatment of cancer | - |
dc.title | The role of CDK4/6 inhibitors in early breast cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.date.updated | 2021-07-09T08:27:02Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34087775 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS0960977621003805.pdf | 328.25 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License